TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient has pain caused by advanced cancer (local recurrence or metastatic disease)~2. Patient reporting average pain score for the last 24 hours is \>/= 4 on a numerical scale from 0 to 10 (0= no pain, 10=the worst possible pain).~3. Patient is receiving mild opioids (e.g. propoxyphene, codeine, tramadol, hydrocodone), mixed agonist/antagonist (e.g. buprenorphine) or no opioids.~4. Patient requires initiation of strong opioid for cancer pain.~5. Patient has the ability to receive morphine or methadone orally.~6. Patient has no known allergy or severe toxicity to morphine or morphine-like drugs (e.g. hydromorphone, oxycodone, oxymorphone, codeine, hydrocodone, levorphanol), or methadone or methadone-like drug (e.g. propoxyphene).~7. Patient has normal cognition defined as normal state of arousal and absence of obvious clinical findings of confusion, memory or concentration deficit.~8. Patient has normal renal function (creatinine and blood urea nitrogen (BUN) within normal limits) \</= 4 weeks of study entry.~9. Patient's performance status (ECOG) is 3 or less.~10. Patient is willing to sign written informed consent.~11. Patient is 18 years of age or older.~12. Patient is able to return to clinic for evaluation by physician day 8 , 15 , 29, 57 and 85 ( +/- 3 days) during study period.~Exclusion Criteria:~1. Patient has concurrent strong opioid for cancer pain, such as morphine, hydromorphone, oxycodone, meperidine, fentanyl, oral transmucosal fentanyl citrate (OTFC), sufentanil, methadone, levorphanol, transdermal fentanyl.~2. Patient is receiving radiation therapy for pain control.~3. Patient is receiving drugs that interacting with methadone, such as (delavirdine, fluconazole, fluvoxamine, bravavir, amprenavir, efavirenz, lopinavir, nelfinavir, nevirapine, carbamazepine, dexamethasone (Patients receiving short term chemotherapy-related doses are permitted) , phenytoin, rifampin, or grapefruit,).~4. Patients are determined incapable of completing the evaluation forms.~5. Severe hypotension, acute or severe asthma, paralytic ileus, gastrointestinal obstruction, severe respiratory depression.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Morphine Capsule (Type: ACTIVE_COMPARATOR): Morphine 15 mg slow release orally every 12 hours + additional doses as needed
- Methadone Capsule (Type: ACTIVE_COMPARATOR): Methadone 5 mg orally every 12 hours + additional as needed doses up to 40-50 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Visual-spatial Attention by Eye Tracking as a Function of Central or Peripheral Visual Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥18 years;~* Patient with a central visual deficit (central scotoma on the visual field: DMLA, cones dystrophy ...) or peripheral (annular scotoma: chronic glaucoma, retinitis pigmentosa ...) or without visual deficit (corrected visual acuity and visual field)~* Patient agreeing to participate in the study and signing informed consent~* Patient affiliated to social security~Exclusion Criteria:~* Pregnant woman~* Patient with known epilepsy~* Major under judicial safeguard, or deprived of liberty~* Major under guardianship or curatorship or admitted to a health or social institution for purposes other than research.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- central vision disorder (Type: EXPERIMENTAL): None
- peripheral vision disorder (Type: EXPERIMENTAL): None
- control (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: fMRI Study of Grasping in Autistic Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* clinical diagnosis of autistic disorder, right-handed, DQ\>50~Exclusion Criteria:~* epilepsia, psychotropic drugs

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Health and Quality of Life One Year After Discharge From the Intensive Care Unit (ICU)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients who are at least 5 days or longer without interruption at the ICU~Exclusion Criteria:~* patients with less than 4 days at the ICU

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- all patients (Type: None): questionnaire for patients with ICU stay at least 5 days or longer without interruption at the ICU

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Dose-finding Study of OPC-6535 in Patients With Active Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with active Crohn's disease~* Patients who have a primary lesion in either the small intestine or the large intestine~* Patients who have been receiving an oral 5-ASA formulation at a fixed regimen and at a fixed dose~* Patients who have either never received enteral nutrition or have been receiving enteral nutrition at a fixed intake of 1200 kcal/day or less~* Either inpatient or outpatient~Exclusion Criteria:~* Patients who have an external fistula (including anal fistula) in which persistent drainage is observed (and who require treatment with antibiotics or synthetic antibacterial agents)~* Patients with short bowel syndrome (and who require intravenous nutritional support due to insufficient intestinal nutrient uptake)~* Patients with an artificial anus~* Patients who have a complication of serious infectious disease (intra-abdominal abscess, etc.)~* Patients who have a complication of malignant tumor~* Female patients who are pregnant, lactating, or possibly pregnant, or who wish to become pregnant during the study period

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Performance Assessment Of The PMD-200 In Subjects With Degenerative Lumbar Spine Disease Who Requires Surgical Procedure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 and less than 65 (18 \< Age \< 65).~* The subject suffer from unilateral degenerative lumbar spine disease~* The subject suffer from leg pain only in one leg, while no pain in the other leg.~* The subject was hospitalized in the neurosurgery department of the hospital in order to undergoes spinal surgery due to the above disease~* A signed Informed Consent Form (ICF) has been obtain from the subject~Exclusion Criteria:~* The subject has a bi-lateral degenerative lumbar spine disease~* The subject is pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- degenerative lumbar spine disease (Type: EXPERIMENTAL): patients who suffer from unilateral degenerative lumbar spine disease, undergo SLR test while being recorded by PMD-200

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Feeding on Pro-Inflammatory Cytokine Response in Neonates Receiving a RBC Transfusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants born \< 31 weeks gestational age~* Between 3 and 7 days old at time of consent~Exclusion Criteria:~* Infants with multiple congenital anomalies~* Infant with suspected/confirmed genetic anomalies~* Infant with suspected/confirmed congenital immune deficiencies

- Gender: ALL
- Minimum Age: 3 Days
- Maximum Age: 6 Months
- Healthy Volunteers: t

Study Arms:
- Intervention: NPO (Type: OTHER): Infants in this group will be made NPO approximately 4 hours prior to receiving a blood transfusion and will remain NPO until approximately 24 hours after the blood transfusion.~Pro-inflammatory cytokine response will be monitored at 3 times points.
- Control: Continue feedings (Type: OTHER): Infants in this group will be allowed to continue feedings during the transfusion at the discretion of the medical team.~Pro-inflammatory cytokine response will be monitored at 3 times points.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antibiotics During Intrauterine Balloon Tamponade Placement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Able to give consent~* Gestational age \> 24 weeks~* Postpartum~* Placement of an IBT within the last 2 hours with plans for it to remain in situ for at least 2 hours~* Primary obstetrician amenable to proceeding with either method of management during the study period.~Exclusion Criteria:~* Age \< 18 years old~* IBT removed within 2 hours of placement~* Chorioamnionitis~* Insufficient documentation of demographics, delivery outcomes, or peripartum events including postpartum hemorrhage, infectious outcomes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): The patient will not receive antibiotics as part of the study, though if at any time her provider chooses to administer antibiotics either prophylactically or for treatment she will not prohibited in any way from this or any other treatment as appropriate.
- Antibiotics (Type: EXPERIMENTAL): The patient will receive a 24-hour course of antibiotics. The primary antibiotic of choice will be cefazolin 1 gm iv q8 hours. If the patient has contraindications to the use of cefazolin including cefazolin allergy, hypersensitivity, or severe beta lactam allergy, then clindamycin 900 mg iv q8 hours will be used instead.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: In Vitro NMR Spectroscopy in Neurological Diseases

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Group 1: Any patient with an unexplained complex neurological disease~* Group 2: Patients with known inborn error of metabolism~* Group 3: patients with known non metabolic disease~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): patients with complex neurological disease of unknown cause
- 2 (Type: None): positive controls : patients with already known metabolic disease for whom we already have CSF or urines
- 3 (Type: None): negative controls: patients with non metabolic neurological disorders of known cause hospitalized for a lumbar puncture

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Immunization To Prevent Acute COPD Exacerbations

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~1. Patient ≥18 years diagnosed with COPD (any stage, the subgroups for the analysis would be based on COPD severity grade)~2. Ability to understand and complete the required QoL questionnaires~3. At least 2 years of clinical history available that includes records of previous moderate/severe exacerbations, influenza and pneumococcal vaccination history comorbidities and previous treatments.~4. Spirometry data (maximum 6 months old, or if not available at enrollment, to be performed as per normal clinical practice at visit 1 +/- one month)~Exclusion criteria:~1. Impossibility to perform prospective follow up~2. Present any immunocompromising condition~3. Present any other respiratory diseases as co-morbidity (subjects with overlap syndromes COPD-asthma will be excluded. Mixed phenotype defined as: symptoms of increased variability of airflow and incompletely reversible airflow obstruction)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults age 18-100 years with Rutherford Classification Stage IV through VI PAD with a recent percutaneous lower extremity arterial angiography with arterial intervention in the past 2 weeks~2. Willingness to sign informed consent~3. Ability to return for follow up visits~4. A female patient of childbearing potential who is sexually active must agree to use adequate contraception from screening until 30 days after receiving the last dose of study drug. Women not of childbearing potential are defined as those who have surgically sterilized (hysterectomy, bilateral oophorectomy, or tubal ligation) or who are post menopausal (defined as at least 2 years since last regular menses). The female patient should not be lactating and must have a negative pregnancy test at screening.~Exclusion Criteria:~Patients will be ineligible for this study if they meet any one of the following criteria:~1. Intolerance to thienopyridines~2. Hypersensitivity to ticagrelor or any component of the product.~3. Concomitant use of oral anticoagulation with vitamin K antagonist, factor Xa inhibitor, or direct thrombin inhibitor~4. History of intracranial hemorrhage~5. History of severe hepatic impairment defined by baseline transaminase greater than or equal to 3x ULN or any elevation in bilirubin~6. Active bleeding~7. Allergy to aspirin~8. Baseline TcPO2 \< 10 mmHg post angiography~9. Resting, pre- procedure heart rate \<50 beats-per-minute without a permanent pacemaker and not on an atrioventricular nodal blocking agent~10. Severe COPD on home oxygen therapy -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Clopidogrel (Type: ACTIVE_COMPARATOR): Clopidogrel 75mg by mouth daily
- Ticagrelor (Type: EXPERIMENTAL): Ticagrelor 90mg by mouth twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Methadone and Medication Abortion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women requesting medication abortion up to 10 weeks gestation~* Fluent English speaking~* Able and willing to receive and send text messages and receive phone calls~* Opioid naive~* Healthy patients with no significant comorbidities~Exclusion Criteria:~* Any history of drug or alcohol use, opioid use in last 30 days, chronic use of pain medications, or use of benzodiazepines.~* Any chronic disease including renal, liver, respiratory or cardiac disease~* Any known allergies to mifepristone, misoprostol, nonsteroidal anti-inflammatory drugs (such as ibuprofen) and methadone.~* Known history of QT prolongation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral methadone (Type: EXPERIMENTAL): Participants will be given a preemptive analgesic in addition to a standard dose of ibuprofen while undergoing early medication abortion with mifepristone and misoprostol (not provided as part of the study). All participants will also be provided with supplementary non- opioid analgesics to be used at their own discretion during the process.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of multiple myeloma~  - Relapsed disease~* Must not be a candidate for stem cell transplantation, has refused transplantation, or has had stem cells collected previously~* Measurable disease, defined by ≥ 1 of the following:~  * Serum monoclonal protein ≥ 1.0 g by protein electrophoresis~ * More than 200 mg of monoclonal protein in the urine on 24 hour electrophoresis~ * Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio~ * Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease)~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) performance status 0-3~* Absolute neutrophil count ≥ 1,000/μL~* Platelet count ≥ 75,000/μL~* Hemoglobin ≥ 8.0 g/dL~* CD4 \> 100/μL~* Creatinine ≤ 3 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No active malignancy with the exception of nonmelanoma skin cancer or in situ cervical or breast cancer~* No uncontrolled infection~* No other co-morbidity that would interfere with patient's ability to participate in trial~PRIOR CONCURRENT THERAPY:~* No limit to prior therapy~* At least 4 weeks since prior melphalan or other myelosuppressive agents~* At least 2 weeks since prior non-myelosuppressive agents (e.g., thalidomide or high-dose corticosteroids)~* No concurrent high-dose corticosteroids~  * Concurrent chronic steroids (maximum dose 20 mg/day prednisone equivalent) allowed if they are being given for disorders other than amyloid (e.g., adrenal insufficiency or rheumatoid arthritis)~ * Concurrent continuation of low level/stable steroid doses for replacement or inhalation therapy allowed~* Concurrent bisphosphonates allowed~* No concurrent immunosuppressive medications such as cyclosporine~* No other concurrent investigational treatment~* No concurrent cytotoxic chemotherapy or external-beam radiotherapy\>~* No other concurrent systemic anti-neoplastic therapy including, but not limited to, immunotherapy, hormonal therapy, or monoclonal antibody therapy~* No concurrent prophylactic hematopoietic growth factors (unless for treatment of an established cytopenia)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Anti-thymocyte Globulin/Melphalan (Type: EXPERIMENTAL): Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m\^2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy